Gestational diabetes mellitus (GDM) poses significant risks to both mother and fetus. As healthcare professionals, it is crucial to adopt a comprehensive approach to manage this condition effectively. This includes screening, early diagnosis, and a combination of dietary, lifestyle, and pharmacological interventions.
Universal screening for GDM should be performed between 24 and 28 weeks of gestation. The preferred method is the two-step approach, which includes an initial glucose challenge test followed by a diagnostic oral glucose tolerance test for those with positive results. Timely diagnosis allows for early intervention, reducing the risk of adverse outcomes.
First-line management of GDM involves dietary modifications and regular physical activity. A registered dietitian should provide individualized meal planning to ensure adequate nutrition while maintaining euglycemia. Exercise, as tolerated, can help improve insulin sensitivity and glycemic control. Regular self-monitoring of blood glucose is also essential.
If lifestyle modifications fail to achieve glycemic targets within one to two weeks, pharmacological therapy should be initiated. Insulin therapy is the gold standard for GDM treatment but oral hypoglycemic agents like metformin or glyburide may be considered as alternatives.
Postpartum care is an integral part of GDM management. Women with GDM should undergo glucose testing at 6-12 weeks postpartum and be counseled about the risk of developing type 2 diabetes. Lifestyle interventions should be continued postpartum to prevent or delay the onset of type 2 diabetes.
Optimal management of GDM requires a comprehensive approach that includes screening, early diagnosis, lifestyle modifications, pharmacological therapy, and postpartum care. Through these strategies, we can improve outcomes for mothers and infants affected by this condition and reduce the long-term risk of type 2 diabetes.
1.
Prostate cancer detection with PET CT and PET MRI is comparable.
2.
Refractory Multiple Myeloma Responsive to Immunotherapy Plus Low-Dose Radiotherapy
3.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
4.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
5.
Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma
1.
Innovative Intraoperative Therapies in Neurosurgical Oncology: Advancing Precision and Outcomes
2.
Unlocking the Potential of Bicalutamide 50 mg: A Revolutionary New Treatment for Prostate Cancer
3.
Holistic Oncology: Advancing Survivorship, Nursing, and Innovative Cancer Care Models
4.
Emerging Chemo-Immunotherapy: New Agents and Mechanisms in Modern Oncology
5.
The Dangers of Supratherapeutic INR: The Need for Increased Awareness and Monitoring
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Thromboprophylaxis In Medical Settings
2.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Efficient Management of First line ALK-rearranged NSCLC
5.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation